Evidence map›Paper›PMID 40458729›Full record

ArticleFrontiers in oncology2025

Combined CA125, NSE, and multiple inflammatory indices for diagnosis of oral squamous cell carcinoma.

Kudelaiti Abudukelimu, Ailifeire Tuerxuntayi, Aikepaer Aierken, Rexiati Keranmu, Duolikun Wufuer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kudelaiti AbudukelimuDepartment of Oral and Maxillofacial Surgery, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
Ailifeire TuerxuntayiDepartment of Gastroenterology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
Aikepaer AierkenDepartment of Medical Research and Translational Management, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
Rexiati KeranmuDepartment of Oral and Maxillofacial Surgery, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
Duolikun WufuerDepartment of Oral and Maxillofacial Surgery, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the changes of serum carbohydrate antigen 125 (CA125), neuron-specific enolase (NSE), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and systemic inflammation response index (SIRI) in patients with oral squamous cell carcinoma(OSCC) and their diagnostic value for OSCC. Subjects and methods: A retrospective analysis was conducted on 136 patients with oral squamous cell carcinoma (OSCC) and 34 healthy controls. Blood routine parameters, as well as serum levels of CA125 and NSE, were obtained for the patients. Additionally, the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic inflammation response index (SIRI) were calculated. The diagnostic value of each marker, both individually and in combination, was evaluated using receiver operating characteristic (ROC) curve analysis. Results: We found that the levels of CA125, NSE, NLR, PLR, and SIRI in the oral squamous cell carcinoma group were significantly higher than those in the healthy control group ( Conclusion: The diagnostic efficiency of OSCC can be enhanced by combining CA125, NSE, NLR, PLR, and SIRI. This combined approach offers high sensitivity and specificity for early diagnosis.

Indexed as

carbohydrate antigen 125diagnostic valueneuron-specific enolaseneutrophil-to-lymphocyte ratiooral squamous cell carcinomaplatelet-to-lymphocyte ratiosystemic inflammation response index

Identifiers

PMID40458729
PMCPMC12127425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.